tissue restoration News
-
Xeltis lands €15 million European financing from EIB
The European Investment Bank (EIB) has signed a €15 million quasi-equity financing agreement with Xeltis. The EIB’s non-dilutive financing will support the acceleration of clinical programmes for three of Xeltis’ revolutionary, restorative devices. The financing is being made available under the European Guarantee Fund (EGF), an EIB Group initiative in partnership with EU Member ...
By XELTIS BV
-
Chrysalis BioTherapeutics Receives $10.4 Million From BARDA to Continue Development of TP508 as a Nuclear Countermeasure
Chrysalis BioTherapeutics, Inc., a clinical-stage biotechnology company focused on the development of regenerative medicines to save lives, announced today that the Biomedical Advanced Research and Development Authority (BARDA) part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services executed options to add $10.4 ...
-
Chrysalis BioTherapeutics Receives BARDA Contract for Over $10 million
Chrysalis BioTherapeutics, Inc. today announced that the Biomedical Advanced Research and Development Authority (BARDA), an agency of the US government’s Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response, has awarded Chrysalis a contract (HHSO100201900016C) to support the continued development of TP508, rusalatide acetate, as a ...
-
SANUWAVE Health Announces Expansion of Ametus Group Distribution Partnership
SANUWAVE Health, Inc. (OTCQB: SNWV), focused on the development and commercialization of a robust and innovative advanced wound care product portfolio for the repair and regeneration of skin and vascular structures, announced today that the Company has entered into a non-exclusive sales and marketing agreement with Ametus to market and sell the Company’s portfolio of wound care products in ...
-
BlueRock Therapeutics to Participate at Upcoming Conferences
BlueRock Therapeutics, LP, an engineered cell therapy company leveraging its novel CELL+GENE™ platform to develop regenerative medicines for intractable diseases, today announced that the company will present at the following upcoming conferences. Presentation details are as follows: BIO International Convention Corporate Presentation Date: Tuesday, June 4, 2019 Time: 2:15 p.m. EDT ...
-
BlueRock Therapeutics to Present at 2019 Cell & Gene Meeting on the Mediterranean
BlueRock Therapeutics, LP, an engineered cell therapy company leveraging its novel CELL+GENE™ platform to develop regenerative medicines for intractable diseases, today announced its participation in the inaugural Cell & Gene Meeting on the Mediterranean to be held April 23-25 in Barcelona, Spain. Emile Nuwaysir, Ph.D., President and Chief Executive Officer of BlueRock, and Vice ...
-
BlueRock Therapeutics to Present at 2019 Cell & Gene Meeting on the Mesa
BlueRock Therapeutics, today announced that Emile Nuwaysir, Ph.D., Chief Executive Officer of BlueRock and Vice Chairman of the Alliance for Regenerative Medicine (ARM), will present at the Cell & Gene Meeting on the Mesa, to be held Oct. 2-4 in Carlsbad, Calif. The following are specific details regarding BlueRock’s participation at the conference: Event: BlueRock Therapeutics ...
-
Ncardia and BlueRock Therapeutics Announce Collaboration Agreement and Licensing of Process Development Technologies for the Manufacture of iPSC-derived Cardiomyocytes
Ncardia and BlueRock Therapeutics today announced an agreement covering process development technologies for the manufacture of induced pluripotent stem cell (iPSC)-derived cardiomyocytes. Under the terms of the agreement, Bluerock gains access to Ncardia’s large-scale production processes and intellectual property for the production of iPSC-derived cardiomyocytes for therapeutic use. ...
-
Regenerative Medicine: The Field Has Come a Long Way and Now is Having its Moment
The scientific community has regarded regeneration as a topic of interest for thousands of years. Long before it was dubbed ‘Regenerative Medicine’, this type of medical intervention was applauded by healthcare professionals for its successful outcomes. Early discoveries, such as skin graft procedures for facial reconstructions, have greatly influenced the field as we know it today. ...
-
BlueRock Therapeutics Appoints Seth Ettenberg
BlueRock Therapeutics, LP today announced the addition of Seth Ettenberg, Ph.D. to the company’s senior leadership team. In his role as Chief Scientific Officer, Dr. Ettenberg will oversee BlueRock’s research and discovery efforts, focused on the application and expansion of BlueRock’s cell+gene platform to the creation of engineered cellular medicines. “We are thrilled ...
-
KLISBio to unveil cutting-edge silk-based technology platform at 2022 Digital RESI Conference
Milan, Italy (March 21, 2022) – Today, KLISBio, a MedTech company challenging the status quo in regenerative medicine by leveraging a silk-based multidisciplinary technology platform, announced its attendance 2022 Digital RESI. The conference will be held March 22-24, 2022 through a virtual platform. KLISBio’s designated attendee to Digital RESI Conference is Gabriele Grecchi, CEO ...
By KLISBio
-
TIKOMED’S ILB® resolves inflammatory scarring and promotes functional tissue repair in data published in npj Regenerative Medicine
A new study on TIKOMED’s lead drug candidate, ILB®, was published in npj Regenerative Medicine today. The peer-reviewed data from rodent and human disease models showed that ILB® leads to tissue remodelling, reduced fibrosis and functional tissue regeneration – observations indicating the potential of ILB® to alleviate fibrotic diseases. Professor Ann Logan, from the ...
By TIKOMED AB
-
QXMedical Licenses Bioresorbable Embolic Technology from U of MN
QXMédical acquired the world-wide exclusive rights to the bioresorbable embolic technology developed by researchers and physicians at the University of Minnesota to fill a clinical need for resorbable and drug-loadable microspheres and hydrogels. Embolics are used by interventional radiologists and oncologists to occlude vessels for a variety of clinical indications. Current market leaders ...
By QXMedical
-
BlueRock Therapeutics Announces Closeout of First Cohort in Phase 1 Trial in Patients with Advanced Parkinson’s Disease
BlueRock Therapeutics, a clinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer AG, announced the closeout of the first of two cohorts in its ongoing Phase 1 (Ph1), open-label trial of pluripotent stem cell-derived dopaminergic neurons in patients with advanced Parkinson’s disease. The purpose of the Ph1 clinical trial is to evaluate the safety, tolerability and ...
-
BlueRock Therapeutics in Collaboration with Memorial Sloan Kettering Cancer Center Receives IND Clearance for DA01 in Parkinson`s Disease
BlueRock Therapeutics, a preclinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer AG, in collaboration with Memorial Sloan Kettering Cancer Center (MSK), announced today that the U.S. Food and Drug Administration (FDA) has cleared their Investigational New Drug (IND) application to proceed with a Phase 1 (Ph1) study in patients with advanced Parkinson’s disease (PD). ...
-
BlueRock Therapeutics Receives Permission from Health Canada for DA01 Trial in Parkinson’s Disease
BlueRock Therapeutics LP, a clinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer AG, announced that Health Canada has given permission to initiate “Phase 1 Safety and Tolerability Study of MSK-DA01 Cell Therapy for Advanced Parkinson’s Disease (PD).” This is the first trial in Canada to study pluripotent stem cell-derived dopaminergic neurons in patients ...
-
First Five Patients Successfully Treated with atHeart Medical’s Novel reSept Atrial Septal Defect Occluder in U.S. IDE Pivotal Trial
atHeart Medical, a medical device company dedicated to establishing the new standard of care for closure of atrial septal defects (ASD), today announced the successful treatment of the first five patients in its ASCENT ASD U.S. Investigational Device Exemption (IDE) pivotal trial. This study, the company’s first in the US, will evaluate the safety and efficacy of the reSept ASD Occluder. ...
-
BlueRock Therapeutics Announces First Patient Dosed in Canada in Phase 1 Trial in Patients with Advanced Parkinson’s Disease
BlueRock Therapeutics, a clinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer AG, announced today the dose administration for the first patient in Canada in partnership with the University Health Network in a Phase 1 (Ph1), open-label trial of pluripotent stem cell-derived dopaminergic neurons in patients with advanced Parkinson’s disease. The purpose of the Ph1 ...
-
Lineage establishes exclusive worldwide collaboration with Genentech for the development and commercialization of Opregen Rpe Cell Therapy for the treatment of ocular disorders
Genentech Will Pay Lineage $50 Million Upfront Eligible to Receive a Total of $670 Million in Upfront and Milestone Payments Conference Call to Discuss Collaboration Planned for 8 a.m. ET Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), today announced that Lineage and its subsidiary, Cell Cure Neurosciences Ltd., have entered into an exclusive worldwide collaboration and ...
-
Bayer acquires BlueRock Therapeutics to build leading position in cell therapy
Implied total company value of up to USD 1 billion, inclusive of 40.8 percent stake currently held by Bayer Initial focus in neurology, cardiology, and immunology with start of first clinical program in Parkinson’s disease expected later this year BlueRock Therapeutics to continue to operate as an independent company Bayer AG and BlueRock Therapeutics today announced an agreement ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you